Do you want to read an article? Please log in or register.
Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study
Am J Gastroenterol
Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A, Guizzetti L, Bessissow T, Jairath V
doi: 10.14309/ajg.0000000000003212
Inflammatory Bowel Disease
Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study
J Crohns Colitis
Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S
doi: 10.1093/ecco-jcc/jjaf052
Inflammatory Bowel Disease
Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
J Crohns Colitis
Gros B, Constantine-Cooke N, Kennedy J, Elford AT, O'Hare C, Noble C, Jones GR, Arnott ID, Lees CW, Plevris N
doi: 10.1093/ecco-jcc/jjae188
Further Publications
Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China
BMC Gastroenterol
Zhang H, Ding XL, Xu YH, Wu J, Wang YY, Liu SX, Yan J, Liu H, Tian ZB, Liu AL
doi: 10.1186/s12876-025-04125-1
RECOMMENDED
Inflammatory Bowel Disease
Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Fuentes-Valenzuela E, Bastón-Rey I, García-Alonso FJ, Elosua A, Zabalza San Martín L, Leo Carnerero E, Garcia de la Filia I, Pedraza Pérez A, Sáiz Chumillas RM, Pascual Oliver A, Muñoz Villafranca C, Moreno V, Suárez Ferrer C, Molina G, Ferreiro-Iglesias R, Vega Villaamil P, Gardeazábal Mateos D, Segarra-Ortega JX, Garrido Marín A, Doallo AI, Alonso-Galán H, Brunet-Mas E, Jimenez García N, López Romero-Salazar F, Velayos B, Carballo-Folgoso L, Pérez Santamaría C, Mata Román L, Núñez Ortiz A, Barrio J, Barreiro-de Acosta M, Gutiérrez-Casbas A, Young GETECCU group
doi: 10.1093/ecco-jcc/jjaf058
Inflammatory Bowel Disease
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety
BMC Gastroenterol
Parra RS, de Sá Brito Fróes R, Magro DO, da Costa Ferreira S, de Mello MK, de Azevedo MFC, Damião AOMC, de Sousa Carlos A, Barros LL, de Miranda MLQ, Vieira A, Sales MPM, Zabot GP, Cassol OS, Tiburcio Alves AJ Jr, Lubini M, Machado MB, Flores C, Teixeira FV, Coy CSR, Zaltman C, Chebli LA, Sassaki LY, Féres O, Chebli JMF
doi: 10.1186/s12876-025-03656-x
Inflammatory Bowel Disease
Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN
Inflamm Bowel Dis
Yerushalmy-Feler A, Spencer EA, Bergstein S, Mitrova K, Hradsky O, Bramuzzo M, Wlazlo M, Olbjørn C, Rungoe C, Weil N, Turner D, Cohen S
doi: 10.1093/ibd/izaf166
Inflammatory Bowel Disease
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis
Clin Gastroenterol Hepatol
Honap S, St-Pierre J, Colwill M, Patel K, Le Berre C, Caron B, Nogami A, Kobayashi T, Altwegg R, Laharie D, Hebuterne X, Nachury M, Roblin X, Uzzan M, Kotze PG, Lukáš M, Vieujean S, D'Amico F, Albshesh A, Guillo L, Fumery M, Nancey S, Ye BD, Bergemalm D, Halfvarson J, Buisson A, Karmiris K, Rubin D, Vicaut E, Peyrin-Biroulet L, ATTRACT Study Group
doi: 10.1016/j.cgh.2025.07.025
Inflammatory Bowel Disease
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data
BMC Gastroenterol
Dignass A, Teich N, Kaiser S, Sünwoldt J, Dünweber C, Weinhold I, Borchert J, Kudernatsch R
doi: 10.1186/s12876-025-04022-7